DK1167537T3 - Fremgangsmåde til fremstilling af et monoklonalt antistof - Google Patents

Fremgangsmåde til fremstilling af et monoklonalt antistof

Info

Publication number
DK1167537T3
DK1167537T3 DK00912975T DK00912975T DK1167537T3 DK 1167537 T3 DK1167537 T3 DK 1167537T3 DK 00912975 T DK00912975 T DK 00912975T DK 00912975 T DK00912975 T DK 00912975T DK 1167537 T3 DK1167537 T3 DK 1167537T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibody
producing
hybridoma
immortalized
cell
Prior art date
Application number
DK00912975T
Other languages
English (en)
Inventor
Chihiro Kusunoki
Atsushi Fukushima
Original Assignee
Japan Tobacco Inc
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc, Amgen Fremont Inc filed Critical Japan Tobacco Inc
Application granted granted Critical
Publication of DK1167537T3 publication Critical patent/DK1167537T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK00912975T 1999-03-30 2000-03-30 Fremgangsmåde til fremstilling af et monoklonalt antistof DK1167537T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8792999 1999-03-30
PCT/JP2000/002022 WO2000058499A1 (fr) 1999-03-30 2000-03-30 Procede pour la production d'anticorps monoclonal

Publications (1)

Publication Number Publication Date
DK1167537T3 true DK1167537T3 (da) 2008-11-10

Family

ID=13928616

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00912975T DK1167537T3 (da) 1999-03-30 2000-03-30 Fremgangsmåde til fremstilling af et monoklonalt antistof

Country Status (8)

Country Link
US (1) US8236530B2 (da)
EP (1) EP1167537B1 (da)
AT (1) ATE402267T1 (da)
AU (1) AU754808B2 (da)
CA (1) CA2368734C (da)
DE (1) DE60039596D1 (da)
DK (1) DK1167537T3 (da)
WO (1) WO2000058499A1 (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
SK14432003A3 (sk) 2001-04-26 2004-07-07 Biogen, Inc. Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
KR101603632B1 (ko) * 2006-09-10 2016-03-16 글리코토페 게엠베하 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
CN101588817B (zh) * 2006-09-10 2013-06-12 葛莱高托普有限公司 骨髓白血病来源的细胞在抗体表达中的用途
EP1911766A1 (en) * 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
AU2013203482B2 (en) * 2006-09-10 2015-08-27 Glycotope Gmbh Fully human high yield production system for improved antibodies and proteins
EP2067041A2 (en) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarkers and assays for the treatment of cancer
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
NZ578701A (en) 2007-02-09 2012-02-24 Genentech Inc Anti-robo4 antibodies and uses therefor
CA2680549A1 (en) 2007-03-12 2008-09-18 Alan D. D'andrea Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
AU2010258094B2 (en) 2009-06-10 2013-09-05 Stephen Sanig Research Institute Ltd. Methods of generating cells exhibiting phenotypic plasticity
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
ES2565208T3 (es) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anticuerpos anti-VEGF-C y métodos de uso de los mismos
RU2609658C2 (ru) 2009-12-21 2017-02-02 Дженентек, Инк. Состав, содержащий антитело
CA2813738A1 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
BR112014004065A2 (pt) 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor
BR112015022210A8 (pt) 2013-03-13 2018-01-23 Genentech Inc formulações de anticorpo
SG10201705525VA (en) 2013-03-13 2017-08-30 Genentech Inc Formulations with reduced oxidation
SI2968467T1 (sl) 2013-03-13 2020-11-30 F. Hoffmann-La Roche Ag Pripravki z zmanjšano oksidacijo
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
AR095348A1 (es) 2013-03-15 2015-10-07 Genentech Inc Medios de cultivo celular y métodos de producción de anticuerpos
CA2903596C (en) 2013-03-15 2023-10-03 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
PT3049441T (pt) 2013-09-27 2020-01-21 Hoffmann La Roche Formulações de anticorpos anti-pdl1
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
KR102447878B1 (ko) 2013-12-17 2022-09-26 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
MX2017003121A (es) 2014-09-15 2017-08-02 Genentech Inc Formulaciones de anticuerpos.
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
EP3253784B1 (en) 2015-02-04 2020-05-06 Genentech, Inc. Mutant smoothened and methods of using the same
CN107771076A (zh) 2015-06-17 2018-03-06 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
SG11201804951SA (en) 2015-12-30 2018-07-30 Genentech Inc Use of tryptophan derivatives for protein formulations
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
MX2018008347A (es) 2016-01-08 2018-12-06 Hoffmann La Roche Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3.
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
WO2017159699A1 (en) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
TWI825098B (zh) 2018-05-18 2023-12-11 德商葛萊高托普公司 抗ｍｕｃ１抗體
MA52968A (fr) 2018-06-23 2021-04-28 Hoffmann La Roche Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
EP3823611A1 (en) 2018-07-18 2021-05-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
AU2019319822A1 (en) 2018-08-08 2021-03-18 Genentech, Inc. Use of tryptophan derivatives and L-methionine for protein formulation
AU2019342133A1 (en) 2018-09-21 2021-04-22 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
IL299039A (en) 2020-06-16 2023-02-01 Genentech Inc Methods and preparations for the treatment of triple-negative breast cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) * 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6475787B1 (en) * 1989-07-28 2002-11-05 Wyeth Method for producing monoclonal antibodies
CA2124967C (en) * 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies

Also Published As

Publication number Publication date
US20060059575A1 (en) 2006-03-16
CA2368734C (en) 2005-08-23
DE60039596D1 (de) 2008-09-04
AU3456300A (en) 2000-10-16
CA2368734A1 (en) 2000-10-05
EP1167537B1 (en) 2008-07-23
US8236530B2 (en) 2012-08-07
EP1167537A1 (en) 2002-01-02
ATE402267T1 (de) 2008-08-15
AU754808B2 (en) 2002-11-28
WO2000058499A1 (fr) 2000-10-05
EP1167537A4 (en) 2005-05-04

Similar Documents

Publication Publication Date Title
DK1167537T3 (da) Fremgangsmåde til fremstilling af et monoklonalt antistof
DK0610046T3 (da) Ekspressionsvektorer kodende for bispecifikke fusionsproteiner og fremgangsmåder til fremstilling af biologisk aktive, bispecifikke fusionsproteiner i en pattedyrscelle
NZ324076A (en) A composition comprising an immunoglobulin having an affinity constant for binding to predetermined human antigen and transgenic non-human animals capable of producing heterologous antibodies
DK1583830T3 (da) Fremgangsmåde til fremstilling af rekombinante polyklonale proteiner
DK0419858T3 (da) Hunde-muse-heterohybridom og genfragment, som koder for den konstante region af hundeimmunglobuliner
DE3278203D1 (en) Monoclonal antibodies specific for the human transferrin receptor glycoprotein
DE59007589D1 (de) Verfahren zur Herstellung hetero-bispezifischer Antikörper.
DK0380068T3 (da) Ekspressionssystem til fremstilling af kimære monoklonale antistoffer
DK0773228T3 (da) Fremgangsmåde til fremstilling af monoklonale human-antistoffer og deres anvendelse
DK0613944T3 (da) Fremgangsmåder til regulering af immunresponset under anvendelse af CTLA4-bindende molekyler og IL4-bindende molekyler
NO2007014I1 (no) Bevacizumab (rekombinant humanisert monoklonalt antistoff)
NL300335I1 (nl) Menselijke monoklonale antilichamen tegen epidermale groeifactorreceptor
Shulman et al. Mutations affecting the structure and function of immunoglobulin M
ATE440868T1 (de) Monoklonaler antikírper gegen ein prion protein und dessen verwendung zum nachweis von prionen
DK1597280T3 (da) Fremstilling af monoklone antistoffer ved EBV-transformation af B-celler
DE60014124D1 (de) Antikörper, die spezifisch für fullerene sind
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
DK1092767T3 (da) Serinproteasespecifikke monoklonale antistoffer og anvendelse deraf
ATE217888T1 (de) Monoklonale antikörper gegen leukozyten- spezifische g-protein-gekoppelte rezeptoren
DE69635715D1 (de) Monoklonaler antikoerper spezifisch fuer prostaglandin d synthetase
AU2707992A (en) Monoclonal antibodies to hepatitis c virus
DK0614982T3 (da) Rekombinant vektor til exocellulær fremstilling af antistoffer i enkeltkædeform udtrykt i Bacillus subtilis
DK0733643T3 (da) Membranprotein-polypeptid, som har den funktion at understøtte vækst af præ-B-celler og gen derfor
DK326289A (da) Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden
Raschke Expression of murine IgM, IgD and Ia molecules on hybrids of murine LPS blasts with a Syrian hamster B lymphoma